Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503822 | 1.00 | HPGDS (0.59) | HPGDSPTPN1HPGDCYP1A1CYP1B1 | |
| SCHEMBL9856951 | 0.86 | HPGD (0.57) | HPGDSHPGDCYP1A1CYP1B1LMNA | |
| SCHEMBL4828413 | 0.86 | HPGD (0.57) | HPGDSHPGDCYP1A1CYP1B1LMNA | |
| SCHEMBL9371365 | 0.82 | CYP1A1 (0.56) | HPGDCYP1A1CYP1B1LMNARAB9A | |
| SCHEMBL18288048 | 0.82 | HPGD (0.63) | HPGDCYP1A1CYP1B1LMNARAB9A | |
| SCHEMBL4831696 | 0.81 | HPGD (0.52) | HPGDCYP1A1CYP1B1LMNARAB9A | |
| SCHEMBL4135870 | 0.80 | HPGD (0.61) | HPGDCYP1A1CYP1B1LMNARAB9A | |
| SCHEMBL1671110 | 0.80 | CYP1A1 (0.64) | HPGDCYP1A1CYP1B1LMNARAB9A | |
| SCHEMBL2120169 | 0.79 | PTPN1 (0.55) | HPGDSPTPN1HPGDLMNAKDM4E | |
| SCHEMBL2747356 | 0.79 | HPGD (0.60) | HPGDCYP1A1CYP1B1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109914-A1 | IMIDAZOTHIAZOLE COMPOUNDS AND ANALOGS THEREOF AND METHODS FOR TREATING NEMATODE INFECTIONS IN PLANTS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-04-04 | — | — | US | disclosed |
| WO-2022150920-A1 | IMIDAZOTHIAZOLE COMPOUNDS AND ANALOGS THEREOF AND METHODS FOR TREATING NEMATODE INFECTIONS IN PLANTS | The Governing Council of the University of Toronto (CA) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022050774-A1 | NOVEL IMIDAZOLE DERIVATIVE SALT HAVING ANTIFUNGAL ACTIVITY, AND USE THEREOF | 경희대학교 산학협력단 | 2022-03-10 | — | — | WO | disclosed |
| WO-2021125905-A1 | NOVEL THIAZOLE DERIVATIVE AND USE THEREOF | 가천대학교 산학협력단 | 2021-06-24 | — | — | WO | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-5523307-A | CEREBROVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1996-06-04 | — | — | US | disclosed |
| US-5196439-A | Piperidine compounds useful to treat cerebrovascular diseases | EISAI CO., LTD. (JP) | 1993-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | HPGDS 2154/4885PTPN1 2006/4885HPGD 1962/4885 |
| US-20240109914-A1 | IMIDAZOTHIAZOLE COMPOUNDS AND ANALOGS THEREOF AND METHODS FOR TREATING NEMATODE INFECTIONS IN PLANTS | NISCH, ABAT, ICMT | HPGDS 1367/4885PTPN1 3372/4885HPGD 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.